BIOMAT Database Logo BIOMAT Database Logo

Correlation between breast cancer mucin (BCM) and CA 125 serum levels in patients with active ovarian tumors. 1990

C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal

UI MeSH Term Description Entries
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors.
November 1987, Cancer,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Correlation between peripheral CA-125 levels and ovarian activity.
September 1990, Fertility and sterility,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
[The correlation between the serum concentrations of BCM (breast cancer mucin), CA549 and estradiol in women with breast macrocysts].
February 1991, Medicina clinica,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer.
January 2022, Anticancer research,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Elevated serum CA-125 levels in patients with ovarian fibrothecomas.
January 1993, European journal of cancer (Oxford, England : 1990),
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Serum CA 125 levels and survival in advanced ovarian cancer.
January 1997, Archives of gynecology and obstetrics,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer.
December 1990, Breast cancer research and treatment,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
[Correlation between platelet count and CA-125 in ovarian cancer].
March 2005, Ginekologia polska,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
The relationship between ovarian volume and serum CA-125 levels.
January 2014, European journal of gynaecological oncology,
C Roiz, and T Allende, and J Fernández-García, and J Vivanco, and A Bianco, and A Ruibal
Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer.
January 1989, The International journal of biological markers,
Copied contents to your clipboard!